| 1. |
- Jin, S. Y., et al.
(author)
-
Spectroscopy of 98Cd by two-nucleon removal from 100In
- 2021
-
In: Physical Review C: covering nuclear physics. - 2469-9985. ; 104:2
-
Journal article (peer-reviewed)abstract
- Low-lying states of Cd-98 have been populated by the two-nucleon removal reaction (In-100, Cd-98+gamma) and studied using in-beam gamma-ray spectroscopy at the Radioactive Isotope Beam Factory at RIKEN. Two new gamma transitions were identified and assigned as decays from a previously unknown state. This state is suggested to be based on a pi 1g(/9/2)(-1)2p(1/2)(-2) configuration with J(pi) = 5(-). The present observation extends the systematics of the excitation energies of the first 5(-) state in N = 50 isotones toward Sn-100. The determined energy of the 5(- )state in Cd-98 continues a smooth trend along the N = 50 isotones. The systematics are compared with shell-model calculations in different model spaces. Good agreement is achieved when considering a model space consisting of the pi(1f(5/2), 2p(3/2), 2p(1/2), 1g(9/2)) orbitals. The calculations with a smaller model space omitting the orbitals below the Z = 38 subshell could not reproduce the experimental energy difference between the ground and first 5(-) states in N = 50 isotones, because proton excitations across Z = 38 subshell yield a large amount of correlation energy that lowers the ground states.
|
|
| 2. |
- Gorski, Mathias, et al.
(author)
-
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
- 2021
-
In: Kidney International. - : Elsevier. - 0085-2538 .- 1523-1755. ; 99:4, s. 926-939
-
Journal article (peer-reviewed)abstract
- Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
|
|
